The Latest Cardiac and Vascular News
Collaboration pairs AtaCor’s investigational extravascular ICD lead with Abbott’s investigational extravascular ICD system to deliver potentially life-saving therapies AtaCor plans to initiate a pivotal Investigational Device Exemption (IDE) clinical trial in 2026 to evaluate the investigational extravascular implantable cardioverter defibrillator (EV-ICD) system This initiative furthers Abbott’s leadership in advancing next-generation […]
Abbott’s Volt™ PFA System, the latest generation of cardiac ablation technology, is designed for people battling heart rhythm disorders such as atrial fibrillation (AFib) Pulsed field ablation – or PFA – is a minimally invasive procedure that uses high-energy electrical pulses in targeted…
New data reveal a 78% reduction in cardiovascular disease-related hospitalizations for people living with Type 1 diabetes with prior severe low blood sugar episodes.1 This significant decrease is linked to the use of Libre biowearable technology compared to traditional blood glucose…
Long-term data from the Volt CE Mark Study show strong results out to 12 months in patients receiving pulsed field ablation (PFA) therapy with the Volt™ PFA System The 12-month results of the Volt CE Mark Study confirm the long-term safety and efficacy of the Volt PFA System The data were…
TRILUMINATE™ Pivotal data presented at the American College of Cardiology’s Annual Scientific Session (ACC.25) and simultaneously published in Circulation show the Abbott TriClip system reduces heart failure hospitalizations The latest results highlight significant improvements in…
Abbott’s Volt™ PFA System is designed to provide a new therapy option for people battling heart rhythm disorders such as atrial fibrillation Pulsed field ablation – or PFA – uses high energy electrical pulses for ablation procedures that may offer benefits to targeting and treating tissue…
Coronary Artery Disease (CAD) is the most common heart disease and most frequent cause of death in the U.S., with over 20 million adults affected by this condition Abbott’s investigational Coronary Intravascular Lithotripsy (IVL) System offers a new potential treatment by using sound…
Strengthens the Potential for Improved Patient Outcomes through Improvements in the Quality of Anticoagulation, Enhancing Hemocompatibility in HeartMate 3™ LVAD patients March 04, 2025 08:00 AM Eastern Standard Time PONTE VEDRA, Fla.–(BUSINESS WIRE)–Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapeutics, with […]
The first-of-its-kind TEAM-HF study seeks to improve clinical outcomes in patients with worsening heart failure Trial establishes new, objective criteria to identify patients most at risk for developing end-stage heart failure and potentially offer life-saving therapeutic options sooner…
Enrollment completed ahead of schedule in the global IDE for Abbott’s Volt™ PFA System Global FOCALFLEX trial now underway for Abbott’s TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ Advisor™ HD Grid X Mapping Catheter, Sensor Enabled™, receives U.S. Food and Drug Administration…
